荧光原位杂交检测板在儿科医院全血细胞减少症评估中对骨髓增生异常综合征的应用：一项5年回顾性研究及应用管理
Utility of Fluorescence In Situ Hybridization Panel for Myelodysplastic Syndrome in Evaluation of Cytopenia in a Pediatric Hospital: A 5-Year Retrospective Review and Utilization Management.
作者信息
Bunting Cynthia T, Senior Tal, Susson Yehuda, Rivera Alethia, Saxe Debra, Bunting Silvia T
机构信息
Emory University, Atlanta, GA.
Business Intelligence, Children's Healthcare of Atlanta, GA.
出版信息
Lab Med. 2017 Aug 1;48(3):266-270. doi: 10.1093/labmed/lmx047.
BACKGROUND
MDS FISH was routinely ordered together with chromosome analysis for patients with cytopenia in our hospital. The utility of MDS FISH in the pediatric population is unknown.
OBJECTIVE
To analyze the utility of fluorescence in situ hybridization panel for myelodysplastic syndrome (MDS FISH) in the management of patients with cytopenia.
METHODS
We performed a retrospective review over a 5-year period, from 2009 to 2014 to determine whether chromosome analysis (CA) plus MDS FISH added useful information compared to chromosome analysis alone. Both CA and MDS FISH were performed on 253 bone marrow biopsies from 182 patients.
RESULTS
CA was highly correlated with MDS FISH (P < .0001) and detected all of the abnormalities seen by MDS FISH in 93.7% of the cases. CA is less expensive and detects additional chromosomal abnormalities not tested in the myelodysplastic syndrome panel. We propose MDS FISH should be ordered when CA fails to give adequate results.
背景
在我们医院，血细胞减少症患者的骨髓增生异常综合征荧光原位杂交（MDS FISH）通常与染色体分析一起进行。MDS FISH在儿科人群中的效用尚不清楚。
目的
分析荧光原位杂交检测骨髓增生异常综合征（MDS FISH）在血细胞减少症患者管理中的效用。
方法
我们对2009年至2014年的5年期间进行了回顾性研究，以确定与单独的染色体分析相比，染色体分析（CA）加MDS FISH是否能提供有用信息。对182例患者的253份骨髓活检标本同时进行了CA和MDS FISH检测。
结果
CA与MDS FISH高度相关（P <.0001），并且在93.7％的病例中检测到了MDS FISH所见的所有异常。CA成本较低，并且能检测到骨髓增生异常综合征检测组中未检测到的其他染色体异常。我们建议当CA未能给出足够的结果时应进行MDS FISH检测。
Zotero 插件